Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be at least 18 years old
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 week
Awards & highlights
Study Summary
This trial will test how comfortable three different types of contact lenses are.
Who is the study for?
This trial is for adults over 18 who experience discomfort with their current contact lenses. Participants must not have an active eye infection or significant eye health issues observed under a microscope, and they shouldn't have been in another study within the last month.Check my eligibility
What is being tested?
The study aims to compare the comfort levels of three different types of contact lenses: Bausch + Lomb PureVision, Acuvue Oasys Lenses, and Clariti 1-Day. Each participant will try these lenses to determine which feels best.See study design
What are the potential side effects?
Potential side effects from wearing contact lenses may include dry eyes, irritation, redness, blurred vision, and discomfort. The severity can vary based on individual sensitivity and lens type.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 week
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 week
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Contact lens wear comfort, as assessed by subject reported symptoms in diaries.
Trial Design
3Treatment groups
Active Control
Group I: Acuvue®Oasys® Lenses(senofilcon A)Active Control3 Interventions
Acuvue® Oasys® Lenses (senofilcon A) contact lenses
Group II: Bausch + Lomb PureVision (balafilcon A)Active Control3 Interventions
30-Day Bausch + Lomb PureVision (balafilcon A) contact lenses
Group III: Clariti® 1-Day (Somofilcon A)Active Control3 Interventions
Clariti® 1-Day (Somofilcon A) contact lenses
Find a Location
Who is running the clinical trial?
ORA, Inc.Lead Sponsor
69 Previous Clinical Trials
8,996 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have an eye infection or significant eye exam findings.I am 18 years old or older.
Research Study Groups:
This trial has the following groups:- Group 1: Acuvue®Oasys® Lenses(senofilcon A)
- Group 2: Bausch + Lomb PureVision (balafilcon A)
- Group 3: Clariti® 1-Day (Somofilcon A)
Awards:
This trial has 3 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is this trial currently inviting participants to join?
"The information recorded on clinicaltrials.gov demonstrates that this clinical trial, which was initially posted on August 1st 2014, is not currently open to recruitment and has seen its last update on January 5th 2015. However, four other medical trials are actively seeking volunteers at present."
Answered by AI
Are there any potential harms associated with Acuvue®Oasys® Lenses(senofilcon A)?
"The safety of Acuvue®Oasys® Lenses(senofilcon A) is ranked with a 3 due to Phase 4 trials, indicating that the treatment has been approved."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger